[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.80 -0.98% 81.20 80.80 81.80 81.60 80.00 80.00 44,141 16:35:20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 65.3 15.4 2.5 33.1 377

Ekf Diagnostics Share Discussion Threads

Showing 3401 to 3424 of 3950 messages
Chat Pages: Latest  146  145  144  143  142  141  140  139  138  137  136  135  Older
DateSubjectAuthorDiscuss
05/5/2021
22:26
You may want to check out the sunspot theory as well - it helps rationalise sideways shares.
tongosti
05/5/2021
15:07
70 is a Fibonacci retrace level (for those who follow such things.) CD
cambridgedon
05/5/2021
11:20
Could be a point to buy imho @70p
sirshagalot
05/5/2021
07:46
Edit - correct link added to the above post.
wan
05/5/2021
07:44
Notable Results and commentary - PerkinElmer Q1 Revenues More Than Double on Strong Diagnostics Business May 04, 2021 NEW YORK – PerkinElmer said after the close of the market on Tuesday that its first quarter revenues more than doubled year over year as revenues from its Diagnostics segment spiked sharply. On a conference call following the release of the financial results, PerkinElmer CFO Jamey Mock said that COVID-19-related product and service revenues totaled $550 million in Q1 2021 "propelled primarily by our PCR tests and RNA extraction solutions, as well as our turnkey lab-in-lab testing solutions in the state of California and the United Kingdom." PerkinElmer President and CEO Prahlad Singh said on the call that the firm anticipates surveillance testing for COVID-19 will remain important "for the foreseeable future" with a focus on testing for asymptomatic patients as global economies continue to open. In other parts of the Diagnostics segment, Mock noted strength in the immunodiagnostics business, as well as applied genomics business, and the reproductive health franchise, which returned to profitability for the first time since Q4 2019. Full story - hTTps://www.360dx.com/business-news/perkinelmer-q1-revenues-more-double-strong-diagnostics-business#.YJI7fLVKiF4
wan
05/5/2021
07:17
The full Trellus Health press release - Trellus Health Announces Experienced Leaders to Drive Next Phase of Growth Press Releases | May 03, 2021 Industry veterans from Teladoc Health, Talkspace, Harwood Capital and Polar Capital join executive team and board of directors White Plains, May 3, 2021: Trellus Health, a leading resilience-driven connected health solution for chronic conditions, announced several important additions to its executive team and board of directors. hTTps://trellushealth.com/2021/05/trellus-health-announces-experienced-leaders-to-drive-next-phase-of-growth/ Apart from the notable executive appointments, Trellus Health has also materially added to their Scientific Advisory Board - hTTps://trellushealth.com/about-us/
wan
04/5/2021
19:25
wanttowin/faz - I assume they are either smoke signals or somemone trying to boost the deal count.
boadicea
04/5/2021
17:31
Thanks faz, but surely too many of them to be buy/sell checks ?
wanttowin
04/5/2021
16:24
https://trellushealth.com/category/press-releases/ In Part: "Trellus Health Announces Experienced Leaders to Drive Next Phase of Growth Press Releases | May 03, 2021 Industry veterans from Teladoc Health, Talkspace, Harwood Capital and Polar Capital join executive team and board of directors White Plains, May 3, 2021: Trellus Health, a leading resilience-driven connected health solution for chronic conditions, announced several important additions to its executive team and board of directors. The company named Alex Kozersky as Chief Sales Officer, Bob Birdsong as Chief Marketing Officer and Carole Romasco as Vice President of Product Management. Jaime King was promoted to Vice President of Compliance, Operations, and Human Resources."
mirandaj
04/5/2021
15:27
wantowin- I've seen them ever seen trading volumes became available on the internet. I would imagine they are not trades as dealing costs would be more than the share so maybe market makers checking buy/sell prices. Happy to be corrected.
faz
04/5/2021
14:53
I've added again, this has to be bargain territory imo.
wanttowin
04/5/2021
14:43
Can anyone tell me what all these tiny trades are ?? Lot and lots of 1,2,3,4,5,6, trades ?
wanttowin
04/5/2021
14:08
Certamente :)
tongosti
04/5/2021
14:07
I think the forecasts for EKF have been woeful(in a positive way this year on numerous times). No fault of EKF but given CV19 and a conservative approach by the business they underpromise and over delivery. Last word from me, is from the last results: Whilst necessarily maintaining a conservative approach to forecasting for our core business, we have already announced that our performance for the first quarter of 2021 will be materially ahead of expectations and the same quarter last year. This morning's news that we have expanded a key supply agreement to become a multi-million dollar global supply contract, means that we are confident that trading for the year ending 31 December 2021 will be significantly ahead of already upgraded expectations."
mysteronz
04/5/2021
14:05
Tong, I think you'll find that you mean "two." I use Sharescope and their numbers are not always accurate. CD
cambridgedon
04/5/2021
13:54
You too make me laugh. Didn't I say sharescope?Go check it out and then you will probably understand why you find yourselves in this predicament. Ps. Share price heading down despite daily ramping posts.
tongosti
04/5/2021
12:54
Crossed in the ether! CD
cambridgedon
04/5/2021
12:43
Can you remind us where the £47.4 comes from. It certainly seems a big fall following FY21 which was upgraded at the T/U "Board confident that trading for Y/E Dec21 will be significantly ahead of already upgraded management expectations." Thanks CD
cambridgedon
04/5/2021
12:37
Tongosti...No one wants to engage with you, because what you want to discuss is either irrelevant or incorrect/out of date/ and backward looking. But I feel it should at least be pointed out that based on the most recent trading update, which I believe is conservative, that N-1 Singer analyst Chris Glasper has upgraded his forecast for December 2021 revenues to £64 million and adjusted pre-tax profit to £15.5 million. Effectively demonstrating that you are out of date and irrelevant. Don't bother trying to extend the conversation, it's already over! EKF's CEO stated the PBS was ramping in a very big way, so let's see what the effects from the private sector partner (believed to be Amazon) does in terms of the full year, and importantly beyond.
wan
04/5/2021
12:15
Wan - while you're at it please help us understand why the city's 2022 revenue estimate of only £47m is not a disappointment? Ta. Amazed (!) no one here likes to touch the subject. PS. Please avoid cliches along the lines of "...you're looking at it way beyond 2020".
tongosti
04/5/2021
12:13
CD...Lumira is not competing with EKF. I keep an eye on LumiraDx purely out of interest and the past Ron Zwanziger connection with EKF (not to mention Alere etc), his departure from EKF was apparently due to the arrival of Chris Mills. But I am far more interested in the current managements ambitions and subsequently the multiple opportunities presenting to EKF, including those via MyHealthChecked.
wan
04/5/2021
11:44
Wan, Thanks for this. Clearly this is a hot space at present; however, to what extent is LumiraDx competing with EKF? Also, having kept all my EKF, added to RENX and VRCI free shares and awaiting Trellus I find that I now have a very hefty weighting of healthcare-type exposure ( no complaints, I've made a lot) but unsure whether I need to add any more. What was the attraction of Lumira? Was it the Ron Z connection or something else which you spotted? Best, CD
cambridgedon
04/5/2021
07:51
Pugugly...Indeed, and likewise I am very optimistic about the prospects for EKF's Life Science division, as is indeed CEO Julian Baines, stating in Hastings update article that EKF is now seriously transitioning from a medium sized enzyme manufacturer to a large one in order to scale up and capture all those opportunities that are now presenting themselves. Of course, life science is just one division of EKF, which importantly is also developing and supplying critical elements to diagnostic companies (including EKF's diagnostic division itself). And diagnostics itself has entered a major growth phase - Pandemic Boosts Diagnostics Field with High Revenues and Acquisitions BY ANITA CHAKRAVERTY 20/04/2021 “The perception used to be that diagnostics tended to carry similar development risk to a drug without the potential return of similarly large addressable markets. That perception has changed over the course of the past year,” Gaugler said. The coronavirus pandemic has undoubtedly had a radical impact on the diagnostics field. Several diagnostics companies have benefited enormously from swiftly steering their business models to deal with the surge in testing. Gaugler predicted there would be increasing interest in emerging diagnostic applications, with the diagnostics market expected to grow massively over the next decade. Full story - hTTps://www.labiotech.eu/trends-news/diagnostics-hologic-covid-19/ For a number of reasons I have been keeping tabs on one company in the above article, LumiraDx, Chief Executive Officer Ron Zwanziger. LumiraDx is a good example, among many, of the huge growth prospects for diagnostics. LumiraDx is a point of care diagnostics testing company which has announced a $5 billion merger with a special purpose acquisition corporation and has doubled its footprint at the Maxim Park office complex in Lanarkshire, Scotland.
wan
02/5/2021
19:07
In a major growth sector https://uk.finance.yahoo.com/news/investors-flock-life-sciences-uk-141124535.html Pays your money - only time will tell if a better choice.
pugugly
Chat Pages: Latest  146  145  144  143  142  141  140  139  138  137  136  135  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211022 17:27:20